A Phase 3 interventional study of Follitropin alfa (Gonal-f) and Follitropin alfa (Primapur) in Infertility, Female, sponsored by IVFarma LLC. Completed at 3 sites in Russian Federation. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-04-01.
Sponsored by IVFarma LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to show equivalence with regard to the number of oocytes retrieved between follitropin alfa (pen-injectors) Primapur® and Gonal-f® in woman undergoing IVF/ICSI
552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.
This study's enrollment of 118 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Browse Infertility, Female studies →IVFarma LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Follitropin alfa (Primapur)
Drug: Follitropin alfa (Gonal-f)
Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
Oocytes (Intention-to-Treat, ITT)
The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.
Time frame: From date of randomization up to 18 days
Number of Follicles With Size ≥ 16 mm
The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration
Time frame: From date of randomization up to 16 days
Mature Oocytes
The number of mature oocytes (MII stage of development)
Time frame: From date of randomization up to 18 days
Fertilised Oocytes
The number of fertilised oocytes with the presence of two pronuclei: 2PN
Time frame: From date of randomization up to 19 days
Percentage of Patients With Embryo Transfer
The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up
Time frame: From date of randomization up to 25 days
Total Dose of Follitropin Alfa
The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)
Time frame: From date of randomization up to 16 days
Number of Days of Follitropin Alfa Treatment
The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)
Time frame: From date of randomization up to 16 days
Number of Patients With Follitropin Alfa Dose Correction
The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)
Time frame: From date of randomization up to 16 days
Number of Patients With Cycle Cancellation
The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)
Time frame: From date of randomization up to 16 days
Number of No-responders
The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)
Time frame: From date of randomization up to 8 days
Percentage of Patients With Serum hCG More Than 25 IU/l
Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)
Time frame: From date of randomization up to 42 days
Percentage of Patients With the Evidence for Clinical Pregnancy
Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity
Time frame: The 10th week after embryo transfer
Subjects were screened and enrolled at 3 In Vitro Fertilisation (IVF) centers in Russian Federation from 08.02.2017 - 17.08.2018.
| Milestone | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Started | 55 | 55 |
| Completed | 55 | 55 |
| Not completed | 0 | 0 |
The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.
| Number of retrieved oocytes | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Oocytes (Intention-to-Treat, ITT) | 12.16 ± 7.28 | 11.62 ± 6.29 |
The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration
| Number of follicles | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Number of Follicles With Size ≥ 16 mm | 12.09 ± 6.159 | 11.38 ± 4.965 |
The number of mature oocytes (MII stage of development)
| Number of mature oocytes (MII stage) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Mature Oocytes | 9.64 ± 6.270 | 9.86 ± 5.546 |
The number of fertilised oocytes with the presence of two pronuclei: 2PN
| Number of oocytes with 2PN | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Fertilised Oocytes | 8.127 ± 6.608 | 8.764 ± 5.850 |
The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up
| Participants | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Embryo transfer on day 3 (%) | 11 | 9 |
| Embryo transfer on day 5 (%) | 38 | 40 |
The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)
| Total dose (IU) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Total Dose of Follitropin Alfa | 1532.7 ± 267.2 | 1517.9 ± 255.2 |
The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)
| Days | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Number of Days of Follitropin Alfa Treatment | 9.745 ± 1.075 | 9.727 ± 1.027 |
The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)
| Participants | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Number of Patients With Follitropin Alfa Dose Correction | 13 | 11 |
The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)
| Participants | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Number of Patients With Cycle Cancellation | 0 | 0 |
The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)
| Participants | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Number of No-responders | 0 | 0 |
Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)
| Percentage of patients (%) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Percentage of Patients With Serum hCG More Than 25 IU/l | 34.7 (21.4 to 48.0) | 36.7 (23.2 to 50.2) |
Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity
| Percentage of patients (%) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Percentage of Patients With the Evidence for Clinical Pregnancy | 26.5 (14.1 to 38.9) | 32.7 (19.6 to 45.8) |
Collected over 1 year, 6 month. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primapur (Follitropin Alfa) | 0/55 (0%) | 2/55 (3.6%) | 21/55 (38.2%) |
| Gonal-f (Follitropin Alfa) | 0/55 (0%) | 2/55 (3.6%) | 13/55 (23.6%) |
| Event | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Ovarian hyperstymulation syndromeReproductive system and breast disorders | 0/55 | 2/55 |
| Iatrogenic injuryInjury, poisoning and procedural complications | 1/55 | 0/55 |
| Threatened miscarriagePregnancy, puerperium and perinatal conditions | 1/55 | 0/55 |
| Event | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) |
|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 4/55 | 2/55 |
| Lower abdominal painPregnancy, puerperium and perinatal conditions | 2/55 | 4/55 |
| Lower abdominal painReproductive system and breast disorders | 3/55 | 1/55 |
| Abnormal vaginal bleedingReproductive system and breast disorders | 3/55 | 1/55 |
| Spontaneous miscarriagePregnancy, puerperium and perinatal conditions | 0/55 | 2/55 |
| Decrease in breast sensitivityReproductive system and breast disorders | 2/55 | 0/55 |
| SpottingReproductive system and breast disorders | 2/55 | 0/55 |
| Early Toxicosis During PregnancyPregnancy, puerperium and perinatal conditions | 0/55 | 1/55 |
| Abnormal vaginal bleedingPregnancy, puerperium and perinatal conditions | 0/55 | 1/55 |
| MensesReproductive system and breast disorders | 0/55 | 1/55 |
| Age, Continuous(years) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| Mean | 31.3 ± 2.68 | 30.0 ± 2.71 | 30.65 ± 2.75 |
| Sex: Female, Male(Participants) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| Female | 55 | 55 | 110 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 55 | 55 | 110 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| Russia | 55 | 55 | 110 |
| Body Mass Index (BMI)(kg/m2) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| Mean | 22.0 ± 2.69 | 22.3 ± 3.06 | 22.15 ± 2.87 |
| Duration of infertility(month) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| Mean | 46.4 ± 32.4 | 36.9 ± 26.6 | 41.65 ± 28.22 |
| Antral follicle(Number of antral follicles) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| Mean | 11.2 ± 3.2 | 12.4 ± 2.4 | 11.80 ± 2.87 |
| Anti-mullerian hormone (AMH)(ng per ml) | Primapur (Follitropin Alfa) | Gonal-f (Follitropin Alfa) | Total |
|---|---|---|---|
| Mean | 4.57 ± 2.96 | 5.47 ± 3.82 | 5.02 ± 3.43 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Aug 2018, 18 months.
Results were first posted in Jun 2019, 9 months after primary completion.
Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa